Vallera DA - Search Results

1

CD16xCD33 bispecific killer cell engager (BiKE) activates NK cells against primary MDS and MDSC CD33+ targets.

Gleason MK, Ross JA, Warlick ED, Lund TC, Verneris MR, Wiernik A, Spellman S, Haagenson MD, Lenvik AJ, Litzow MR, Epling-Burnette PK, Blazar BR, Weiner LM, Weisdorf DJ, Vallera DA, Miller JS. Gleason MK, et al. Among authors: vallera da. Blood. 2014 May 8;123(19):3016-26. doi: 10.1182/blood-2013-10-533398. Epub 2014 Mar 20. Blood. 2014. PMID: 24652987 Free PMC article.

2

Promotion of murine marrow alloengraftment and hematopoietic recovery across the major histocompatibility barrier by administration of recombinant human interleukin-1 alpha.

Blazar BR, Widmer MB, Taylor PA, Vallera DA. Blazar BR, et al. Among authors: vallera da. Blood. 1992 Sep 15;80(6):1614-22. Blood. 1992. PMID: 1369829 Free article.

3

Anti-CD3 immunotoxin prevents low-dose STZ/interferon-induced autoimmune diabetes in mouse.

Vallera DA, Carroll SF, Brief S, Blazar BR. Vallera DA, et al. Diabetes. 1992 Apr;41(4):457-64. doi: 10.2337/diab.41.4.457. Diabetes. 1992. PMID: 1376702

4

Effect of recombinant human macrophage colony-stimulating factor in irradiated murine recipients of T-cell-depleted allogeneic or non-depleted syngeneic bone marrow transplants.

Blazar BR, Aukerman SL, Vallera DA. Blazar BR, et al. Among authors: vallera da. Blood. 1992 Mar 15;79(6):1636-42. Blood. 1992. PMID: 1547353 Free article.

5

General strategies in in vivo animal modeling.

Vallera DA, Blazar BR. Vallera DA, et al. Targeted Diagn Ther. 1992;7:63-77. Targeted Diagn Ther. 1992. PMID: 1633310 Review. No abstract available.

6

In vivo administration of anti-CD3 monoclonal antibodies or immunotoxins in murine recipients of allogeneic T cell-depleted marrow for the promotion of engraftment.

Blazar BR, Hirsch R, Gress RE, Carroll SF, Vallera DA. Blazar BR, et al. Among authors: vallera da. J Immunol. 1991 Sep 1;147(5):1492-503. J Immunol. 1991. PMID: 1831826

7

Prevention of murine graft-versus-host disease and bone marrow alloengraftment across the major histocompatibility barrier after donor graft preincubation with anti-LFA1 immunotoxin.

Blazar BR, Carroll SF, Vallera DA. Blazar BR, et al. Among authors: vallera da. Blood. 1991 Dec 1;78(11):3093-102. Blood. 1991. PMID: 1954395 Free article.

8

Pretreatment of murine donor grafts with L-leucyl-L-leucine methyl ester: elimination of graft-versus-host disease without detrimental effects on engraftment.

Blazar BR, Thiele DL, Vallera DA. Blazar BR, et al. Among authors: vallera da. Blood. 1990 Feb 1;75(3):798-805. Blood. 1990. PMID: 1967541 Free article.

9

Toxicity and efficacy of anti-T-cell ricin toxin A chain immunotoxins in a murine model of established graft-versus-host disease induced across the major histocompatibility barrier.

Vallera DA, Carroll SF, Snover DC, Carlson GJ, Blazar BR. Vallera DA, et al. Blood. 1991 Jan 1;77(1):182-94. Blood. 1991. PMID: 1984794 Free article.

10

Autologous bone marrow transplantation in high-risk remission T-lineage acute lymphoblastic leukemia using immunotoxins plus 4-hydroperoxycyclophosphamide for marrow purging.

Uckun FM, Kersey JH, Vallera DA, Ledbetter JA, Weisdorf D, Myers DE, Haake R, Ramsay NK. Uckun FM, et al. Among authors: vallera da. Blood. 1990 Nov 1;76(9):1723-33. Blood. 1990. PMID: 2224122 Free article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

228 results

Search Page

Filters